2023 - Research.com Medicine in Belgium Leader Award
His primary areas of study are Internal medicine, Diabetes mellitus, Endocrinology, Type 2 diabetes and Pharmacology. His biological study spans a wide range of topics, including Gastroenterology, Placebo and Surgery. His Diabetes mellitus study combines topics from a wide range of disciplines, such as Psychiatry and Schizophrenia.
His Endocrinology study frequently draws connections between adjacent fields such as Rimonabant. In his study, which falls under the umbrella issue of Type 2 diabetes, Pioglitazone and Diabetes risk is strongly linked to Insulin resistance. His research in Pharmacology intersects with topics in Sitagliptin, Saxagliptin, Canagliflozin and Kidney disease.
André Scheen focuses on Internal medicine, Endocrinology, Diabetes mellitus, Type 2 diabetes and Gynecology. The study incorporates disciplines such as Surgery and Cardiology in addition to Internal medicine. His study in Obesity, Glucagon, Glucose tolerance test and Carbohydrate metabolism is carried out as part of his studies in Endocrinology.
His studies deal with areas such as Disease, Pediatrics and Risk factor as well as Diabetes mellitus. André Scheen has researched Type 2 diabetes in several fields, including Metformin, Intensive care medicine, Metabolic syndrome, Pharmacology and Type 2 Diabetes Mellitus. The Gynecology study combines topics in areas such as Coronary heart disease and Nutritional status.
His scientific interests lie mostly in Type 2 diabetes, Internal medicine, Diabetes mellitus, Gynecology and Metformin. His Type 2 diabetes research is multidisciplinary, relying on both Heart failure, Kidney disease, Insulin, Disease and Pharmacology. His Pharmacology study combines topics in areas such as Saxagliptin, Pharmacotherapy and Glucagon-like peptide 1 receptor.
His Internal medicine study incorporates themes from Endocrinology, Cardiology and Type 2 Diabetes Mellitus, Empagliflozin, Dapagliflozin. His work in Diabetes mellitus addresses subjects such as Placebo, which are connected to disciplines such as Clinical trial. His Metformin research is multidisciplinary, incorporating perspectives in Sulfonylurea, Randomized controlled trial, Gliflozin and Oncology.
André Scheen mostly deals with Type 2 diabetes, Internal medicine, Diabetes mellitus, Type 2 Diabetes Mellitus and Pharmacology. His Type 2 diabetes research incorporates themes from Metformin, Hypoglycemia, Diuretic, Intensive care medicine and Disease. The various areas that he examines in his Internal medicine study include Empagliflozin, Endocrinology and Cardiology.
The various areas that he examines in his Endocrinology study include Bone metastasis, Prostate cancer and Rheumatology. His Diabetes mellitus study combines topics from a wide range of disciplines, such as Stroke, Adverse effect, Clinical trial and Insulin. His Type 2 Diabetes Mellitus research is multidisciplinary, incorporating perspectives in Institutional repository, Weight loss, Kidney disease, Overweight and Evidence-based practice.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy;Bernard Charbonnel;David J A Eckland;Erland Erdmann.
The Lancet (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
Luc F Van Gaal;Aila M Rissanen;André J Scheen;Olivier Ziegler.
The Lancet (2005)
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.
Nathalie Esser;Sylvie Legrand-Poels;Jacques Piette;André J. Scheen.
Diabetes Research and Clinical Practice (2014)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
André J Scheen;Nick Finer;Priscilla Hollander;Michael D Jensen.
The Lancet (2006)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino.
Effect of valsartan on the incidence of diabetes and cardiovascular events.
John McMurray;R Holman;Steven Haffner;M Bethel.
The New England Journal of Medicine (2010)
RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient
André Scheen;Chantal Mathieu.
Revue médicale de Liège (2012)
Clinical pharmacokinetics of metformin.
André J. Scheen.
Clinical Pharmacokinectics (1996)
Roles of circadian rhythmicity and sleep in human glucose regulation
E. Van Cauter;K. S. Polonsky;André Scheen.
Endocrine Reviews (1997)
Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty.
Françoise Luyckx;Claude Desaive;Albert Thiry;W. Dewe.
International Journal of Obesity (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: